Cargando…
Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676614/ https://www.ncbi.nlm.nih.gov/pubmed/33079601 http://dx.doi.org/10.1161/CIRCGEN.120.003061 |
| _version_ | 1783611809159184384 |
|---|---|
| author | Gill, Dipender Burgess, Stephen |
| author_facet | Gill, Dipender Burgess, Stephen |
| author_sort | Gill, Dipender |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7676614 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76766142020-11-23 Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes Gill, Dipender Burgess, Stephen Circ Genom Precis Med Research Letters Lippincott Williams & Wilkins 2020-08-13 /pmc/articles/PMC7676614/ /pubmed/33079601 http://dx.doi.org/10.1161/CIRCGEN.120.003061 Text en © 2020 The Authors. Circulation: Genomic and Precision Medicine is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. |
| spellingShingle | Research Letters Gill, Dipender Burgess, Stephen Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title | Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title_full | Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title_fullStr | Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title_full_unstemmed | Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title_short | Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes |
| title_sort | use of a genetic variant related to circulating fxa (activated factor x) levels to proxy the effect of fxa inhibition on cardiovascular outcomes |
| topic | Research Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676614/ https://www.ncbi.nlm.nih.gov/pubmed/33079601 http://dx.doi.org/10.1161/CIRCGEN.120.003061 |
| work_keys_str_mv | AT gilldipender useofageneticvariantrelatedtocirculatingfxaactivatedfactorxlevelstoproxytheeffectoffxainhibitiononcardiovascularoutcomes AT burgessstephen useofageneticvariantrelatedtocirculatingfxaactivatedfactorxlevelstoproxytheeffectoffxainhibitiononcardiovascularoutcomes |